Ultragenyx (RARE) announced the FDA has accepted for review the resubmitted biologics license application seeking accelerated approval for UX111 AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome Type A. The FDA set a Prescription Drug User Fee Act action date of September 19.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Wins FDA IND Clearance for UX016 Therapy
- Ultragenyx announces FDA clearance of UX016 investigational new drug application
- Ultragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa
- Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
- Microsoft reinstated, Ralph Lauren upgraded: Wall Street’s top analyst calls